Clarus Therapeutics Holdings, Inc., recently announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for claims that cover its oral testosterone replacement product, Jatenzo (testosterone undecanoate).
Related posts
-
‘So empowering’: Community blossoms through inclusive art project in Roselle
A Roselle sculpture project celebrates artists with special needs. -
United celebrates, American sues as city updates gate allocation at O’Hare
Who’s on first at O’Hare International Airport? Here’s a look at Chicago’s gate update as United... -
Why your ComEd bills are going up this month
Residential ComEd customers in Illinois will pay more for electricity starting this month, the utility confirmed...